| Similar Articles |
|---|
 |
Nurse Practitioner
May 2011
Stacey A. Seggelke |
Hitting the target for inpatient glycemic management An understanding of glycemic treatment options for hospitalized patients is essential for good patient outcomes.   |
Nursing
November 2009
Christine Kessler |
Glycemic control in the hospital: How tight should it be? Based on recent studies, the answer to that question remains controversial. This article will explore this issue and present current best practices for caring for a patient in the hospital who has diabetes or hyperglycemia. |
American Family Physician
August 1, 2004
Mayfield & White |
Insulin Therapy for Type 2 Diabetes: Rescue, Augmentation, and Replacement of Beta-Cell Function New insulin preparations and a better understanding of insulin physiology provide more options for family physicians attempting to effectively tailor insulin therapy to the needs of individual patients. |
American Family Physician
August 1, 2004 |
Your Insulin Therapy A patient guide to managing diabetes with insulin. |
Salon.com
January 22, 2001
Janet Lafler |
I'm a cyborg and I love it My portable insulin pump never strays from my side, but I feel more human with the technology than without it... |
American Family Physician
November 1, 2000 |
Diabetes: Flexible Insulin Regimens for People with Type 1 Diabetes What is insulin?... How do I use insulin?... What is a flexible insulin regimen?... When should I take insulin?... |
American Family Physician
July 15, 2006
Jennifer D. Goldman-Levine |
Insulin Detemir (Levemir) for Diabetes Mellitus Insulin detemir is suitable as basal insulin in a basal-bolus regimen. In limited research, it has been shown to cause slightly fewer episodes of minor hypoglycemia and no weight gain in patients with type 1 and 2 diabetes, which is a benefit that must be balanced against its higher price. |
American Family Physician
September 15, 2006
Havas & Donner |
Tight Control of Type 1 Diabetes: Recommendations for Patients Physicians play an important role in helping type 1 diabetes patients make essential lifestyle changes to help reduce the risk of microvascular and macrovascular complications. |
Nursing Management
January 2012
Lawrence et al. |
Type 2 Diabetes: Growing to Epic Proportions Affecting all age groups and all aspects of a person's life, diabetes is a major public health issue worldwide, requiring lifelong behavioral and lifestyle changes and support. |
BusinessWeek
February 28, 2005
Gene G. Marcial |
J&J May Pump Up Animas Animas, a little-known maker of small glucose pumps, could take a big share of the insulin-measurement market. |
American Family Physician
January 1, 2003
Jennifer B. Marks |
Perioperative Management of Diabetes Diabetic patients who require surgery present special challenges in perioperative management. Special attention must be paid to prevention and treatment of metabolic derangements. |
The Motley Fool
June 27, 2005
Stephen D. Simpson |
Sniffing Out a Possible Diabetes Blockbuster Inhaled insulin has been a Holy Grail of diabetes care. Will it live up to lofty expectations? Pfizer, Sanofi-Aventis, and Lilly are all interesting in their own right as high-quality pharmaceutical companies, and more aggressive investors should take a look at Nektar and Alkermes, as well. |
The Motley Fool
July 17, 2006
Stephen D. Simpson |
Medtronic's Evolutionary Revolution Step by step, Medtronic may change how diabetes is treated. |
American Journal of Nursing
January 2012
Andrew D. Harding |
Increasing the Use of `Smart' Pump Drug Libraries by Nurses: A Continuous Quality Improvement Project Improving the quality of nursing care, as well as the organization's culture of safety and its financial discipline, are each further reasons to support the use of smart pump technology. |
Chemistry World
August 23, 2013
Jessica Cocker |
Plant protein regulates diabetes treatment A plant protein has been used to make a new class of glucose-responsive polymer nanogels that could one day negate the need for diabetes patients to constantly monitor their blood glucose levels and inject themselves with insulin. |
Managed Care
May 2006
Fadia T. Shaya & Deshpande |
New Treatment Approaches To Diabetes The goal of diabetes management is maintaining glycemic control while targeting quality of life improvements. |
Managed Care
December 2003
Thomas Morrow |
Can Amylin Analogue Lead To Better Diabetes Control? Maintaining tight glucose control is difficult to accomplish, but adding amylin to the mix may be the answer. |
American Family Physician
May 1, 2005 |
Diabetic Ketoacidosis: What It Is and How to Prevent It An informative patient hand-out on the condition, its causes, triggers, prevention and instructions on what do if the conditions presents. |
American Family Physician
May 1, 2001 |
Treatment Options for Type 2 Diabetes -- What's Available? What are the different steps in managing my diabetes? What are the different types of medicines used to treat type 2 diabetes and how do they work? |
Food Processing
August 2013
Mark Anthony |
The Condemnation of Carbohydrates: A Food Manufacturers Guide to Understanding Diabetes The commonly held notion that sugar intake equals diabetes is a kind of unofficial dogma. But like many dogmas, this one falls apart upon closer examination. |
BusinessWeek
November 12, 2007
Reena Jana |
My iPod, My Cell, My Insulin Pump In an effort to provide better care for the world's surging population of diabetics, medical device makers are teaming up with industrial designers and seeking inspiration in popular consumer products such as MP3 players and cell phones. |
Pharmaceutical Executive
May 1, 2009 |
The Fate of Mannkind Al Mann has sunk almost $1 billion of his own money into a new insulin delivery system. Will FDA be persuaded? |
AskMen.com
April 29, 2001
Joshua Levine |
Do You Have Diabetes? Diabetes is not contagious; people cannot "catch" it from one another. However, certain factors can increase one's risk of developing the disease... |
Chemistry World
November 3, 2011
Andrew Turley |
Taming Osmosis for Steady Drug Delivery Inspired by how plants transport fluids, a German start up has developed a pump that uses osmosis to deliver a liquid drug without electrical power or mechanical parts. |
The Motley Fool
October 2, 2007
Brian Orelli |
Amylin's Bittersweet FDA News Diabetes drug moves ahead, but not as much as the company wanted. If the FDA rejection was due to safety issues, that wouldn't bode well for Amylin's plans to develop the active ingredient in SYMLIN as a weight-loss drug. Investors, take note. |
Pharmaceutical Executive
October 1, 2005 |
Changing Diabetes An interview with Novo Nordisk's president of U.S. operations Martin Soeters on how a nation that leads the world in diabetes research does such a poor job of treating it. Here, he offers some solutions. |
HHMI Bulletin
Fall 2012
Sarah C. P. Williams |
The Fat You Can't See Without the liver acting as a filter and energy producer, a person can't survive, and no artificial organ can perform all of its duties. But in one in three Americans -- and similar numbers in other developed nations -- the liver has lost its luster. |
American Family Physician
March 15, 2001
Goutham Rao |
Insulin Resistance Syndrome Insulin resistance can be linked to diabetes, hypertension, dyslipidemia, cardiovascular disease and other abnormalities. Because resistance usually develops long before these diseases appear, identifying and treating insulin-resistant patients has potentially great preventive value... |
IEEE Spectrum
October 2011
Joseph M. Smith |
Wireless Health Care Wireless technologies are about to transform health care, and not a moment too soon |
Chemistry World
April 8, 2014
Sarah Kenwright |
Olive oil may offer diabetes protection Spanish scientists say increasing the amount of olive oil in your diet could reduce your risk of developing metabolic syndrome and type 2 diabetes. |
Chemistry World
November 9, 2010
Andrew Turley |
Company snapshot: Novo Nordisk As the results for the third quarter of this year roll in, one pharma major - Danish company Novo Nordisk - seems to have done better than most with its diabetes medicines. |
Managed Care
October 2005
Thomas Morrow |
Incretin Hormones Poised For Better Control of Diabetes Enhanced management continues due to a greater understanding of the intricate glucose balance and the shortfalls of existing medications. |
American Family Physician
May 1, 2005
David E. Trachtenbarg |
Diabetic Ketoacidosis Initial evaluation of patients with DKA includes diagnosis and treatment of precipitating factors. Education to prevent recurrence should be offered to all patients, including how to manage sick days and when to call a physician. |
American Family Physician
September 15, 2006 |
Type 1 Diabetes: What You Should Know A patient guide: What is type 1 diabetes?... What should I do if I have type 1 diabetes?... How do I control my blood sugar level?... What if my blood sugar level gets too low or too high?... etc. |
Managed Care
April 2005 |
Diabetes Costs Rise, But so Does Adherence A typical health plan can expect endocrine and diabetes agents to amount to 6% to 8% of total utilization costs, with spending on these agents to increase between 11% and 15% 2005. |
Pharmaceutical Executive
March 1, 2006
Ron Feemster |
Holding Their Breath: Inhaled Insulin Exubera, Pfizer's inhaled-insulin therapy, is carving out a new market for diabetes drugs. Four more companies are looking for their share. |
Chemistry World
September 3, 2014
Phillip Broadwith |
Novo Nordisk quits inflammation R&D and cuts jobs Novo Nordisk is terminating its inflammatory disease R&D programs after the company's leading rheumatoid arthritis drug candidate failed in clinical trials. |
Managed Care
May 2007
Rachel M. Renshaw |
Keys to Diabetes Control? Patience, Persistence, and Perseverance Careful attention to a comprehensive treatment plan could forestall or prevent the need to add drugs and costs to a patient's regimen. |
Nursing
September 2010
Margaret M. Bolton |
Sounding the alarm about metabolic syndrome Any health problem that affects a third of American adults is sure to impact your nursing practice. Metabolic syndrome, a growing and commonly silent condition, poses a significant public health crisis. |
IEEE Spectrum
January 2011
Sandra Upson |
Bionic Pancreas Artificial organ could improve control over diabetes |
The Motley Fool
October 27, 2005
Stephen D. Simpson |
What's New With Novo? Novo Nordisk is a good play on diabetes, but will new drugs reduce the need for insulin? Investors, take note. |
Pharmaceutical Executive
November 1, 2014
William Looney |
Dane in America Jesper Hoiland, Novo Nordisk's President for North America, assesses the challenges and opportunities during his first year at the helm of the diabetes franchise leader's biggest affiliate market. |
The Motley Fool
May 20, 2009
Brian Orelli |
Joining to Treat, and Beat, Diabetes Medical-device maker Medtronic and drugmaker Eli Lilly are teaming up to co-promote the companies' diabetes products to doctors and patients. |
AskMen.com
Alex Santoso |
What You Should Know About Diabetes Not many men understand what diabetes is, why it's very bad for them (it is one of the leading causes of impotence), what they can do to avoid getting it or how to treat it. |
The Motley Fool
July 27, 2007
Rich Duprey |
Sniffing Out Bentley's New Patent To succeed in insulin therapy, the generic drugmaker must overcome patent expiration. Investors, take note. |
The Motley Fool
November 30, 2007
Brian Orelli |
Analyzing Amylin Amylin Pharmaceuticals holds its R&D day to update investors on the marketing strategy of its two diabetes products, as well as the development of its pipeline. |
American Family Physician
May 1, 2001
Beatriz Luna & Mark N. Feinglos |
Oral Agents in the Management of Type 2 Diabetes Mellitus Currently, there are five distinct classes of hypoglycemic agents available, each class displaying unique pharmacologic properties... |
Managed Care
July 2004
Udaya M. Kabadi |
Cost-Effective Management of Hyperglycemia in Patients with Type 2 Diabetes Using Oral Agents Sulfonylureas are cost-effective and also may be the only oral agents that inhibit processes inducing hyperglycemia by improving insulin secretion and insulin resistance. New long-acting agents hold even greater promise. |
Chemistry World
May 7, 2009
Phillip Broadwith |
Polymers release insulin in response to glucose trigger Chinese researchers have developed polymer nanoparticles that can release insulin in response to changes in glucose concentration, creating a potential treatment for diabetes. |
Chemistry World
June 30, 2014
Phillip Broadwith |
Inhaled insulin approved in US Mannkind's Affreza is aimed at reducing the need for patients to inject themselves with insulin so frequently. |
